CSF2 and T-cell non-Hodgkin lymphoma: In the current study, we found the disease progression caused by GM-CSF in T-cell lymphoma was associated with the decreases of tumor-infiltrating T cells and granzyme B release, which could be restored with PD-1 therapy.